Al-Dawaa Medical Services Company — Cyborg Score 7/10

Strong
Pharmaceutical Retail & Healthcare Services

Strategic Profile

The company operates through three segments: Retail, Wholesale, and Logistics. Al-Dawaa sells its pharmaceutical products through a network of pharmacies, as well as online and wholesale channels, positioning itself as an integrated healthcare services provider with significant distribution reach in Saudi Arabia.

Cyborg Score Rationale

Al-Dawaa demonstrates solid fundamentals with consistent double-digit revenue growth, a dominant market position with 900+ pharmacies across 100+ cities, and a healthy dividend yield. The company shows strategic diversification across retail, wholesale, and logistics with manufacturing capabilities in medical devices.

Top Insights

  • Company's revenue in the last twelve months is 6.59B SAR, up 12.56% year-over-year, with annual 2024 revenue of 6.45B and 12.36% growth
  • Customer base has surpassed the five million mark
  • Al-Dawaa Medical Services dividend yield is 4.59%
  • The company has five subsidiaries: Al-Dawaa Medical Services Company, Holinx GmbH, Ronzac GmbH, Glanzzen, and Premier Medical Devices Manufacturing Company

Named Competitors

  • Pharmacy and Medical Retail — Large pharmacy chain competitor in Saudi Arabia
  • Healthcare Services — Hospital and medical services competitor

Recent Developments

  • (Mar 2025) Quarterly revenue of 1.65B SAR with 8.85% growth for Q1 FY2025
  • (2024) Full-year revenue reached 6.45B SAR, maintaining double-digit growth trajectory
  • (2024) Maintained market leadership position with 900+ pharmacy locations across Kingdom

Open the full interactive Al-Dawaa Medical Services Company report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →